ClinicalTrials.gg
RecruitingNCT05489705DISCOVER-HCMUpdated Aug 19, 2026

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

An observational study in Obstructive Hypertrophic Cardiomyopathy, sponsored by Bristol-Myers Squibb. Recruiting at 101 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Bristol-Myers Squibb · Observational

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,700
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 10 open to participants now, 15 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.

Planned enrollment
Largest of 15
1,700 · median 200
Started
2022
with 3 others
Observational
15 of 32
9 open now
Primary completion
2029-08
later than 13 of 14 live
Registered
11th of 32
by date

Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one has the largest planned enrollment of the 15 observational ones that give a count, is one of 4 that started in 2022, is one of 15 observational ones, reaches primary completion later than 13 of the 14 other live ones, and was the 11th registered.

Cardiomyopathy, Hypertrophic

365 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 118 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

10 of the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 82 Cardiomyopathy, Hypertrophic studies recruiting now, 56 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment.

United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.

Europe Sub-Study: The purpose of this study is to evaluate the effectiveness and safety of mavacamten in patients with symptomatic obstructive HCM in the real-world setting.

03

Conditions studied

  • Obstructive Hypertrophic Cardiomyopathy

Keywords

  • Obstructive hypertrophic cardiomyopathy
  • Obstructive HCM (oHCM)
  • Mavacamten
  • Heart failure
  • oHCM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include adult participants with symptomatic obstructive HCM who are receiving pharmacological treatment for obstructive HCM (for example, BBs, non-DHP CCBs, disopyramide, and/or mavacamten) as part of routine care in the United States or Europe.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age at the time of .
  • Willing and able to provide written informed consent form (ICF) and any required privacy authorization prior to the initiation of study procedures (or in those situations where consent cannot be given by participants, consent provided by their legally acceptable representatives)

United States Sub-Study

  • Diagnosis of obstructive HCM consistent with 2020 American Heart Association/American College of Cardiology (AHA/ACC) guidelines.

    • Obstructive HCM is defined clinically by the presence of increased LV wall thickness ≥ 15 mm (or ≥ 13 mm with positive family history of HCM) in a nondilated ventricular chamber that is not solely explained by abnormal loading conditions (eg, another cardiac or systemic disease) and peak LVOT gradient of ≥ 30 mmHg at rest or with provocation.
  • Has documented of ≥ 55% recorded by echocardiography within the last 6 months.
  • Symptoms consistent with functional class II-IV.
  • Receiving beta blocker (BB)s, non-dihydropyridine calcium. channel blockers (nonDHP CCBs), disopyramide, and/or mavacamten (once available) as part of routine clinical care; or currently receiving no treatment due to intolerance or failure of prior treatment (eg, BBs, non-DHP CCBs, or disopyramide) for obstructive HCM.

European Sub-study

  • Diagnosis of obstructive HCM consistent with the most recent European Society of Cardiology (ESC) and American Heart Association/American College of Cardiology (AHA/ACC) guidelines
  • Documented LVEF of ≥55% recorded by TTE
  • Documented symptoms consistent with NYHA functional class II-III at enrollment or within 6 months prior to enrollment (if not available at enrollment).
  • As part of routine clinical care for obstructive HCM: receiving BBs, non-DHP CCBs, disopyramide; initiating mavacamten at enrollment; or currently receiving no treatment due to intolerance or failure of prior treatment (e.g., BBs, non-DHP CCBs, or disopyramide).

Exclusion criteria

Exclusion Criteria

  • Known phenocopy disease (e.g., Fabry disease, amyloidosis) or LV hypertrophy associated with hypertension.
  • Documentation of any fixed obstruction of the outflow tract such as aortic valve stenosis or replacement.
  • Prior treatment of obstructive HCM with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation [ASA]) within 6 months prior to enrollment; participants with an unsuccessful myectomy or percutaneous ASA performed > 6 months prior to enrollment may be enrolled.
  • Naïve to treatment for obstructive HCM (ie, never treated with BBs, nonDHP CCBs, or disopyramide).

United States Sub-Study

  • Receiving an therapeutic agent for obstructive HCM (eg, myosin-inhibitors other than mavacamten) in an interventional clinical trial at participant enrollment.
  • Previously or currently enrolled in a long-term safety extension study of mavacamten (eg, EXPLORER-HCM [ClinicalTrials.gov, NCT03470545], MAVA-LTE [NCT03723655], PIONEER-OLE [NCT03496168], VALORHCM [NCT04349072], or MAVERICK [NCT03442764])

European Sub-study

  • Receiving an investigational therapeutic agent or any cardiac myosin inhibitor and/or modulators for obstructive HCM at patient enrolment
  • Previously or currently enrolled in other HCM registry studies (e.g., TORCH, REMY, EU-PASS)
  • Previously or currently enrolled in a study of mavacamten (e.g., EXPLORER-HCM [ClinicalTrials.gov, NCT03470545], MAVA-LTE [NCT03723655], PIONEER-OLE [NCT03496168], VALOR-HCM [NCT04349072], MAVERICK [NCT03442764], or MEMENTO [NCT2264899])
  • Previously treated with mavacamten
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,700 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Mavacamten

    Participants will receive mavacamten as prescribed by a physician according to standard of care for symptomatic oHCM

    Drug: Mavacamten

  • Beta-blocker (BB) / non-dihydropyridine (non-DHP) calcium channel blocker (CCB) / disopyramide

    Participants will receive BB/non-DHP CCB/disopyramide as prescribed by a physician according to standard of care for symptomatic oHCM

    Drug: Non-mavacamten symptomatic oHCM therapy

Interventions

  • DrugMYK-461Studies of MYK-461MYK-461 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As per product label

  • DrugNon-mavacamten symptomatic oHCM therapy

    Including Beta-blocker (BB), non-dihydropyridine (non-DHP) calcium channel blocker (CCB) and/or disopyramide as per product label

06

What researchers measure

Primary outcomes

  1. Incidence rate of new or worsening heart failure due to systolic dysfunction among participants with symptomatic obstructive HCM during periods of exposure to mavacamten and other oHCM treatment

    Systolic dysfunction defined as symptomatic Left Ventricular Ejection Fraction (LVEF) \< 50%. United States participants only.

    Time frame: Up to 5 Years

  2. Change in resting left ventricular outflow tract (LVOT) gradient from baseline

    European Participants only

    Time frame: Up to 18 months

Secondary outcomes

  1. Occurrence of arrhythmia

    Incidence rates of participants with arrhythmia (new onset)

    Time frame: Baseline, and up to 18 months (European participants), or 5 Years (United States participants)

  2. New or worsening heart failure due to systolic dysfunction

    Symptomatic left ventricular ejection fraction (LVEF) \<50%. European Participants only

    Time frame: Baseline and up to 18 months

  3. Proportion of participants with a resting or provoked peak left ventricular outflow tract (LVOT) gradient below 50 mmHG

    European participants only

    Time frame: Baseline and up to 18 months

  4. Proportion of participants with a resting or provoked peak left ventricular outflow tract (LVOT) gradient below 30 mmHG

    European participants only

    Time frame: Baseline and up to 18 months

  5. Occurrence of Major Adverse Cardiovascular Events (MACE)

    A composite endpoint consisting of non-fatal acute Myocardial Infarction (MI), stroke, hospitalization due to Heart Failure (HF) and Cardiovascular (CV) mortality. United States participants only.

    Time frame: Up to 5 Years

  6. Occurrence of non-fatal acute Myocardial Infarction (MI)

    United States participants only

    Time frame: Up to 5 Years

  7. Occurrence of Stroke

    United States participants only

    Time frame: Up to 5 Years

  8. Occurrence of hospitalization due to heart failure

    Time frame: Baseline, and up to 18 months (European participants), or 5 Years (United States participants)

  9. Occurrence of cardiovascular mortality

    United States participants only

    Time frame: Up to 5 Years

  10. Occurrence of all-cause mortality

    Time frame: Baseline, and up to 18 months (European participants), or 5 Years (United States participants)

  11. Evaluation of functional responses: New York Heart Association (NYHA) function class

    Percentage of Participants Whose NYHA Class Changes

    Time frame: Baseline, and up to 18 months (European participants), or 5 Years (United States participants)

  12. Evaluation of functional responses: Left Ventricular Outflow Tract (LVOT) gradient

    Mean Change From Baseline in LVOT Gradients At Rest and Provoked

    Time frame: Baseline, and up to 18 months (European participants), or 5 Years (United States participants)

  13. Evaluation of functional responses: LVEF

    Mean Change from Baseline in LVEF

    Time frame: Baseline, and up to 18 months (European participants), or 5 Years (United States participants)

  14. Evaluation of patient reported outcome measure: Kansas City Cardiomyopathy Questionnaire 23 (KCCQ-23)

    The KCCQ-23 is a disease-specific health status instrument composed of 23 items that quantifies the domains of physical limitations, symptoms, self-efficacy, social limitation and quality of life from heart failure. Scores range from 0-100, in which higher scores reflect better health status. United States participants only

    Time frame: Baseline, and up to 5 Years

  15. Evaluation of patient reported outcome measure: EuroQol Five Dimensions Questionnaire (5-level) (EQ-5D-5L): Health Utility Index

    The EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L health utility index and EQ Visual Analog Scale (VAS). EQ-5D-5L health utility index is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participants select an answer for each of the 5 dimensions that best matches his/her health "today". Responses are used to generate a weighted summary index, which ranges from 0 to 1.00. A higher score indicates better health and positive changes from baseline indicate improvement of health. United States participants only

    Time frame: Baseline, and up to 5 Years

  16. Evaluation of patient reported outcome measure: EQ-5D-5L: VAS

    The EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and VAS. The VAS self-rating records the participant's own assessment of his or her overall health status at the time of completion, on a vertical line VAS with scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). A higher score indicates better health and positive changes from baseline indicate improvement of health status. United States participants only

    Time frame: Baseline, and up to 5 Years

  17. Evaluation of biomarkers of response: NT-proBNP

    Change From Baseline in Serum concentration of NT-proBNP. United States participants only

    Time frame: Baseline, and up to 5 Years

  18. Evaluation of biomarkers of response: Cardiac troponin

    Change From Baseline in Serum Concentration of Cardiac Troponins. United States participants only

    Time frame: Baseline, and up to 5 Years

07

Study locations

76 of 101 sites recruiting
  • Alaska Heart Institute
    Anchorage, Alaska 99508, United States
    Recruiting
    • Ahmed Abuzaid, Site 0023 · Contact907-561-3211
  • Pima Heart and Vascular
    Tucson, Arizona 85704, United States
    Recruiting
    • Greg Koshkarian, Site 0025 · Contact000-000-0000
  • UAMS
    Little Rock, Arkansas 72205-7199, United States
    Recruiting
    • Srikanth Vallurupalli, Site 0007 · Contact501-686-5545
  • Local Institution - 0037
    La Jolla, California 92037, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Keck School of Medicine of USC-Usc
    Los Angeles, California 90033, United States
    Recruiting
    • Eugene DePasquale, Site 0057 · Contact323-442-6130
  • Stanford Health Care Hospital & Clinics
    Palo Alto, California 94304, United States
    Recruiting
    • Matthew Wheeler, Site 0012 · Contact
  • University Of California San Francisco Medical Center
    San Francisco, California 94117, United States
    Recruiting
    • Theodore Abraham, Site 0021 · Contact
  • UC Denver, AMC
    Aurora, Colorado 48377, United States
    Recruiting
    • David Raymer, Site 0050 · Contact720-848-5300
  • Local Institution - 0067
    Hartford, Connecticut 06106, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • Patrick Bering, Site 0081 · Contact202-877-5975
  • Local Institution - 0065
    Jacksonville, Florida 32209, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0046
    Honolulu, Hawaii 96813, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Chicago Dept of Medicine
    Chicago, Illinois 60637, United States
    Recruiting
    • Gene Kim, Site 0063 · Contact773-702-9396
  • Indiana. University
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Roopa Rao, Site 0013 · Contact317-962-9700
  • Franciscan Physician Network-Indiana Heart Physicians
    Indianapolis, Indiana 46237, United States
    Recruiting
    • George Lolay, Site 0016 · Contact317-893-1712
  • Local Institution - 0045
    Iowa City, Iowa 52242, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 0059
    Baltimore, Maryland 21201, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • MedStar Health Research Institute
    Baltimore, Maryland 21218, United States
    Recruiting
    • Sandeep Jani, Site 0030 · Contact
  • Harvard (Massachusetts General Hospital)
    Boston, Massachusetts 02114, United States
    Recruiting
    • Albree Tower-Rader, Site 0024 · Contact617-724-5434
  • Harvard Medical School - Brigham and Women's Hospital (BWH)
    Boston, Massachusetts 02215, United States
    Recruiting
    • Carolyn Ho, Site 0068 · Contact617-732-5500
  • Spectrum Health Medical Group
    Grand Rapids, Michigan 49525, United States
    Recruiting
    • David Fermin, Site 0073 · Contact616-885-5000
  • Henry Ford Health System
    West Bloomfield, Michigan 48322, United States
    Recruiting
    • Karthikeyan Ananthasubramaniam, Site 0034 · Contact
  • Minneapolis Heart Institute Foundation
    Minneapolis, Minnesota 55407, United States
    Recruiting
    • Robert Fraser, Site 0010 · Contact612-863-3900
  • Cardiology Associates Research, Llc
    Tupelo, Mississippi 38801, United States
    Recruiting
    • Barry Bertolet, Site 0062 · Contact904-392-2469
  • St. Luke's Mid-America Heart Institute
    Kansas City, Missouri 64111, United States
    Recruiting
    • Michael Nassif, Site 0069 · Contact
  • Local Institution - 0033
    Kansas City, Missouri 66160, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Washington University
    St Louis, Missouri 63110, United States
    Recruiting
    • Richard Bach, Site 0036 · Contact314-362-1963
  • CHI Health Reseach Center
    Omaha, Nebraska 68124, United States
    Recruiting
    • Amjad Kabach, Site 0070 · Contact
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Dmitry Nemirovsky, Site 0029 · Contact551-996-5870
  • Local Institution - 0026
    Morristown, New Jersey 07960, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Bassett Medical Center
    Cooperstown, New York 13326, United States
    Recruiting
    • Mun Hong, Site 0006 · Contact607-547-4582
  • Local Institution - 0009
    New York, New York 10019, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Mount Sinai Hospital
    New York, New York 10029, United States
    Recruiting
    • Johanna Contreras, Site 0035 · Contact917-751-5850
  • Saint Francis Hospital
    Roslyn, New York 11576, United States
    Recruiting
    • Allen Jeremias, Site 0075 · Contact631-707-2586
  • WMCHealth Advanced Physician Services
    Valhalla, New York 10595, United States
    Recruiting
    • Srihari Naidu, Site 0053 · Contact914-598-7651
  • Focus Clinical Research
    Charlotte, North Carolina 28207, United States
    Recruiting
    • Aamer Qurehshi, Site 0040 · Contact888-635-0552
  • Duke University Health System
    Durham, North Carolina 27710, United States
    Recruiting
    • Andrew Wang, Site 0022 · Contact
  • Christ Hospital Health Network
    Cincinnati, Ohio 45219, United States
    Recruiting
    • Wojciech Mazur, Site 0015 · Contact513-721-8881
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Recruiting
    • Anene Clair Ukaigwe, Site 0041 · Contact216-286-1023
  • Local Institution - 0003
    Cleveland, Ohio 44195, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • St. Luke's University Health Network
    Bethlehem, Pennsylvania 18015, United States
    Recruiting
    • Jamshid Shirani, Site 0043 · Contact718-430-3314
  • Local Institution - 0076
    Lancaster, Pennsylvania 17603, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
    • Timothy Wong, Site 0027 · Contact
  • Geisinger Health System
    Wilkes-Barre, Pennsylvania 18711, United States
    Recruiting
    • Vernon Mascarenhas, Site 0056 · Contact570-808-6020
  • Prisma Health - Upstate
    Greenville, South Carolina 29605, United States
    Recruiting
    • Josh Doll, Site 0042 · Contact864-455-7727
  • Tristar Centennial Medical Ctr
    Nashville, Tennessee 37203, United States
    Recruiting
    • Bryan Doherty, Site 0048 · Contact347-949-3060
  • Saint Thomas Health
    Nashville, Tennessee 37205-2018, United States
    Recruiting
    • Mark Zenker, Site 0019 · Contact615-269-4545
  • North Texas Cardiology Center
    Dallas, Texas 75208, United States
    Recruiting
    • Manavjot Sidhu, Site 0018 · Contact214-933-7430
  • Baylor Scott & White Research Institute
    Dallas, Texas 75246, United States
    Recruiting
    • Robert Gottlieb, Site 0008 · Contact
  • The Methodist Hospital, Methodist Cancer Cencer
    Houston, Texas 77030, United States
    Recruiting
    • Sherif Nagueh, Site 0058 · Contact713-441-2850
  • BI Research Center
    Houston, Texas 77084, United States
    Recruiting
    • Asif Akhtar, Site 0039 · Contact281-944-3610
  • Baylor Scott & White The Heart Hospital Plano
    Plano, Texas 75093, United States
    Recruiting
    • David Rawitscher, Site 0028 · Contact469-800-6390
  • Baylor Scott & White Medical Centre - Temple
    Temple, Texas 76508, United States
    Recruiting
    • Vinh Nguyen, Site 0051 · Contact254-724-5119
  • The Rector and Visitors of the Univ of Virginia
    Charlottesville, Virginia 22908, United States
    Recruiting
    • Christopher Kramer, Site 0011 · Contact434-982-0853
  • VCU Medical Center
    Richmond, Virginia 23298, United States
    Recruiting
    • Mohammed Makkiya, Site 0080 · Contact804-828-9989
  • Carilion Clinic; Virginia Tech-Carilion School of Medicine
    Roanoke, Virginia 24014, United States
    Recruiting
    • Ali Hama Amin, Site 0044 · Contact540-982-8204
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
    Recruiting
    • Mariko Harper, Site 0052 · Contact206-341-1111
  • WVU Hospitals
    Morgantown, West Virginia 26506, United States
    Recruiting
    • Christopher Bianco, Site 0055 · Contact304-598-4000
  • Local Institution - 0004
    Madison, Wisconsin 53792, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Medical College of Wisconsin, Inc (PI Address)
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Abhinav Sharma, Site 0054 · Contact414-805-6000
  • KH St.Josef Braunau am Inn
    Braunau am Inn, 5280, Austria
    Recruiting
    • Johann Auer, Site 0082 · Contact+437722804510
  • LKH-Univ. Klinikum Graz
    Graz, 8036, Austria
    Recruiting
    • Nicolas Verheyen, Site 0087 · Contact+433163851254
  • Local Institution - 0088
    Innsbruck, 6020, Austria
    Not yet recruiting
    • Site 0088 · Contact
  • Local Institution - 0084
    Klagenfurt, 9020, Austria
    Withdrawn

    Not enrolling at this site — choose another above.

  • Kepler Universitätsklinikum Linz
    Linz, 4021, Austria
    Recruiting
    • Christian Reiter, Site 0086 · Contact4357680836220
  • Local Institution - 0085
    Sankt Pölten, 3100, Austria
    Not yet recruiting
    • Site 0085 · Contact
  • Local Institution - 0083
    Vienna, 1090, Austria
    Not yet recruiting
    • Site 0083 · Contact
  • Local Institution - 0002
    Olomouc, 779 00, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0001
    Prague, 150 00, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Centre Hospitalier Haguenau
    Haguenau, Bas Rhin 67500, France
    Recruiting
    • Charlotte Dagrenat, Site 0092 · Contact33388063435
  • CHU Nantes Hopital Nord Laennec
    Saint-Herblain, Loire Atlantique 44800, France
    Recruiting
    • Nicolas Piriou, Site 0093 · Contact+33240165716
  • Hôpital Saint Vincent-de-Paul
    Lille, Nord 59000, France
    Recruiting
    • Ludovic Appert, Site 0090 · Contact33320874996
  • CHU Amiens-Picardie
    Amiens, Somme 80054, France
    Recruiting
    • Yohann Bohbot, Site 0091 · Contact33322087258
  • Hôpital Sainte Musse
    Toulon, Var 83000, France
    Recruiting
    • Jean-Michel Tartière, Site 0094 · Contact33483772070
  • CHU De Poitiers - Hopital De La Miletrie
    Poitiers, Vienne 86000, France
    Recruiting
    • Benjamin Alos, Site 0089 · Contact33549444444
  • Local Institution - 0117
    Montpellier, 34000, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • Ostalb-Klinikum Aalen
    Aalen, Baden-Wurttemberg 73430, Germany
    Recruiting
    • Stephanie Loebig, Site 0098 · Contact497361550
  • Local Institution - 0101
    Erlangen, Bavaria 91054, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Universitatsklinikum Muenster
    Münster, North Rhine-Westphalia 48149, Germany
    Recruiting
    • Jürgen Sindermann, Site 0100 · Contact+492518347426
  • Praxisklinik Herz Und Gefasse-Klinikum Weisser Hirsch
    Dresden, Saxony 01099, Germany
    Recruiting
    • Gregor Simonis, Site 0099 · Contact493518064440
  • Universitaetsklinikum Leipzig Aoer
    Leipzig, Saxony 04103, Germany
    Recruiting
    • Karsten Lenk, Site 0097 · Contact+4936419324521000000
  • Immanuel Klinikum Bernau
    Bernau, State of Berlin 16321, Germany
    Recruiting
    • Christian Butter, Site 0095 · Contact+493338694644
  • Kardiologische und angiologische Praxen im Spreebogen
    Berlin, 10719, Germany
    Recruiting
    • Wilhelm Haverkamp, Site 0096 · Contact+4930450565906
  • Local Institution - 0002
    Katowice, 40-635, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0001
    Warsaw, 04-628, Poland
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research & Cardiovascular Corp
    Ponce, 00717-1322, Puerto Rico
    Recruiting
    • Jose Vazquez-Tanus, Site 0077 · Contact7872908585
  • Hospital Fundacion Son Llatzer
    Palma de Mallorca, Balearic Islands 07198, Spain
    Recruiting
    • Tomas Ripoll, Site 0109 · Contact+34871202102
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid 28222, Spain
    Recruiting
    • Pablo García Pavia, Site 0104 · Contact+34911917297
  • Hospital Universitario Virgen de La Arrixaca
    El Palmar, Murcia 30120, Spain
    Recruiting
    • Juan Ramon Gimeno Blanes, Site 0105 · Contact+34619068153
  • Hospital Universitario Central de Asturias
    Oviedo, Principality of Asturias 33011, Spain
    Recruiting
    • Rebeca Lorca Gutierrez, Site 0106 · Contact+3498510800033114
  • Hospital Universitario de Burgos
    Burgos, 09006, Spain
    Recruiting
    • Ana Merino Merino, Site 0107 · Contact+34947281800
  • Local Institution - 0102
    Madrid, 28007, Spain
    Withdrawn

    Not enrolling at this site — choose another above.

  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
    Recruiting
    • Maria Alejandra Restrepo Cordoba, Site 0108 · Contact+34913303944
  • Hospital Clinico Universitario Virgen de La Victoria
    Málaga, 29010, Spain
    Recruiting
    • José Manuel García Pinilla, Site 0103 · Contact+34951032349
  • Local Institution - 0113
    London, Greater London SW3 6NP, United Kingdom
    Not yet recruiting
    • Site 0113 · Contact
  • Imperial College Healthcare NHS Trust
    London, Greater London W6 8RF, United Kingdom
    Recruiting
    • Amanda Varnava, Site 0115 · Contact+447532199693
  • University Of Manchester
    Manchester, Greater Manchester M13 9WL, United Kingdom
    Recruiting
    • Andrew Crean, Site 0112 · Contact+441612761234
  • Liverpool Heart and Chest Hospital
    Liverpool, Merseyside L14 3PE, United Kingdom
    Recruiting
    • Robert Cooper, Site 0111 · Contact+441512281616
  • Local Institution - 0110
    Birmingham, West Midlands B15 2GW, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Leeds General Infirmary
    Leeds, West Yorkshire LS1 3EX, United Kingdom
    Recruiting
    • Alex Simms, Site 0114 · Contact+441133922385

Showing the first 100 of 101 sites across 9 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Aug 2029, 84 months after the start.

Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 84 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2022
First posted
Aug 5, 2022
StartActual
Aug 16, 2022
Primary completionEst.
Aug 17, 2029
CompletionEst.
Aug 17, 2029
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05489705
Responsible party
Sponsor
First posted
Aug 5, 2022
Start date
Aug 16, 2022
Primary completion
Aug 17, 2029 (estimated)
Completion
Aug 17, 2029 (estimated)
Last update
Aug 19, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion